{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:06:53Z","timestamp":1793984813238,"version":"4.8.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To demonstrate the safety and feasibility of the Urocross Expander System (formerly branded as XFLO Expander System), an implantable nitinol tissue expander to trea t patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Men of 50 years or older were eligible to participate in the international, prospective, three-arm, open-label EXPANDER-1 trial if they had a prostate volume between 30 and 80\u2009cc, prostatic urethra length between 20 and 60\/80\u2009mm, international prostate symptom score (IPSS)\u2009&gt;\u200913, peak urinary flow (Qmax)\u2009&lt;\u200912\u2009mL\/s, post-void residual (PVR) urine volume\u2009&lt;\u2009250\u2009mL and quality of life (QoL) score\u2009\u2265\u20093. Patients had pre-assigned implant indwell times (1, 6, and 12 months for Arm-1, Arm-2 and Arm-3 respectively) with follow-up through 6 months (Arm-1) and 3 years (Arm-2 and Arm-3) post-retrieval.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Outcome from treated subjects with their 6-month post-retrieval will be presented in this manuscript, as data collection from longer-term follow-up is ongoing. As of May 24, 2021, 39 and 22 men (mean age: 65), respectively, had implants successfully deployed and retrieved without any complications. No cases of implant encrustation were observed. Device- and procedure-related adverse events were predominantly mild to moderate in severity. Three SAEs were reported. Only one patient required catheterization post-implant for more than three days. Improvements in clinical parameters such as IPSS, QoL, PVR and Qmax as well as sexual function were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Preliminary results demonstrate that the Urocross Expander System is a feasible and safe procedure for treating BPH\/LUTS. A strong signal of efficacy justifies further evaluation of this <jats:underline>PR<\/jats:underline>ostatic <jats:underline>U<\/jats:underline>rethral <jats:underline>E<\/jats:underline>xpansion (PURE) procedure. Negative features of earlier generations of prostatic implants such as biocompatibility, migrations and encrustation have possibly been overcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-022-00548-z","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T11:14:13Z","timestamp":1653995653000},"page":"576-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The EXPANDER-1 trial: introduction of the novel Urocross\u2122 Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-0339","authenticated-orcid":false,"given":"Henry H.","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Huei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Shun","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archil","family":"Chkhotua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-7783","authenticated-orcid":false,"given":"Dean S.","family":"Elterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"548_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","volume":"43","author":"KB Egan","year":"2016","unstructured":"Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43:289.","journal-title":"Urol Clin North Am"},{"key":"548_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/bju.15191","volume":"127","author":"S Shamout","year":"2021","unstructured":"Shamout S, Carlson K, Brotherhood HL, Crump T, Baverstock R. Incidence and predictors of early and late hospital readmission after transurethral resection of the prostate: a population-based cohort study. BJU Int. 2021;127:238\u201346.","journal-title":"BJU Int"},{"key":"548_CR3","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24:8802\u201313.","journal-title":"Can J Urol"},{"key":"548_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bju.13714","volume":"119","author":"C Gratzke","year":"2017","unstructured":"Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119:767\u201375.","journal-title":"BJU Int"},{"key":"548_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/bju.12982","volume":"116","author":"F Porpiglia","year":"2015","unstructured":"Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116:278\u201387.","journal-title":"BJU Int"},{"key":"548_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2017.07.005","volume":"72","author":"G Magistro","year":"2017","unstructured":"Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72:986\u201397.","journal-title":"Eur Urol"},{"key":"548_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajur.2017.06.001","volume":"5","author":"ASJ Chung","year":"2018","unstructured":"Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asia J Urol. 2018;5:22\u201327.","journal-title":"Asia J Urol"},{"key":"548_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1756287218793084","volume":"10","author":"J Westwood","year":"2018","unstructured":"Westwood J, Geraghty R, Jones P, Rai BP, Somani BK. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10:327\u201333.","journal-title":"Ther Adv Urol"},{"key":"548_CR9","first-page":"CD013143","volume":"2","author":"EC Hwang","year":"2019","unstructured":"Hwang EC, Jung JH, Borofsky M, Kim MH, Dahm P. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2019;2:CD013143.","journal-title":"Cochrane Database Syst Rev"},{"key":"548_CR10","doi-asserted-by":"publisher","first-page":"175628721982897","DOI":"10.1177\/1756287219828971","volume":"11","author":"P Sountoulides","year":"2019","unstructured":"Sountoulides P, Karatzas A, Gravas S. Current and emerging mechanical minimally invasive therapies for benign prostatic obstruction. Ther Adv Urol. 2019;11:1756287219828971.","journal-title":"Ther Adv Urol"},{"key":"548_CR11","first-page":"e393","volume":"203","author":"HH Woo","year":"2020","unstructured":"Woo HH, Huang CP, Lien CS, Chkhotua A. First-in-human clinical experience with the XFLO Expander System to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2020;203:e393\u2013e394.","journal-title":"J Urol"},{"key":"548_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/OAJU.S11752","volume":"3","author":"AG Papatsoris","year":"2011","unstructured":"Papatsoris AG, Junaid I, Zachou A, Kachrilas S, Zaman F, Masood J, et al. New developments in the use of prostatic stents. Open Access J Urol. 2011;3:63\u201368.","journal-title":"Open Access J Urol"},{"key":"548_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2017.07.005","volume":"72","author":"G Magistro","year":"2017","unstructured":"Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72:986\u201397.","journal-title":"Eur Urol"},{"key":"548_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1464-410X.2011.10342.x","volume":"108","author":"HH Woo","year":"2011","unstructured":"Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2011;108:82\u201388.","journal-title":"BJU Int"},{"key":"548_CR15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.urology.2015.05.046","volume":"86","author":"C Dixon","year":"2015","unstructured":"Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of rez\u016bm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2015;86:1042\u20137.","journal-title":"J Urol"},{"key":"548_CR16","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","DOI":"10.1097\/01.sla.0000133083.54934.ae"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00548-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:09:01Z","timestamp":1660745341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00548-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00548-z","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}